- GSK prepares for patent cliff with $2.5B cost-cutting plan<figure><div><img src="https://imgproxy.divecdn.com/mDk-h3NLB8udDPFuDlI7IPou1i9tJKJYucQXUnhK9vA/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTc3MzEzMjc4LmpwZ…BioPharma Dive · 1h ago↗ source
- Oak Hill Bio merges with RA Capital SPAC; InnoCare's TYK2 drug hits in Phase 3💵 Oak Hill Bio’s SPAC merger: The Angelman syndrome biotech will merge with RA Capital’s blank-check company, called Research Alliance Corporation III, and get about ...Endpoints · 2h ago↗ source
- FDA staff say Replimune's melanoma trial failed to prove RP1 worksFDA staff threw cold water on Replimune’s advanced melanoma drug ahead of a critical meeting with agency advisors, writing that the pivotal study design failed to prove its drug actually works. T…